본문으로 건너뛰기
← 뒤로

Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy.

1/5 보강
Trends in pharmacological sciences 2026 Vol.47(3) p. 244-247
Retraction 확인
출처

Thapa R, Shrestha J, Paudel KR

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.8%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

FLT3 mutations drive acute myeloid leukemia (AML) progression through aberrant signaling, making FLT3 inhibition a key therapeutic strategy.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Thapa R, Shrestha J, Paudel KR (2026). Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy.. Trends in pharmacological sciences, 47(3), 244-247. https://doi.org/10.1016/j.tips.2026.01.009
MLA Thapa R, et al.. "Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy.." Trends in pharmacological sciences, vol. 47, no. 3, 2026, pp. 244-247.
PMID 41735133 ↗

Abstract

FLT3 mutations drive acute myeloid leukemia (AML) progression through aberrant signaling, making FLT3 inhibition a key therapeutic strategy. Current inhibitors show efficacy, yet resistance and toxicity remain challenges. Emerging approaches, including selective inhibitors, proteolysis-targeting chimeras, and protein degraders, offer enhanced potency, sustained suppression, and combinatorial potential, representing a precision-based advancement in AML treatment.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (1)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반